Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edgewise Therapeutics, Inc. (NASDAQ: EWTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Edgewise is a clinical-stage biopharmaceutical company developing therapeutics for muscular dystrophies and serious cardiac conditions, and its filings offer detailed information on clinical progress, financial results, and corporate governance.
Investors can review current reports on Form 8-K that Edgewise files to announce material events, such as clinical data updates for sevasemten in Becker and Duchenne muscular dystrophies, progress in the EDG-7500 CIRRUS-HCM Phase 2 trial in hypertrophic cardiomyopathy, and initiation of Phase 1 studies for EDG-15400 in heart failure. Other 8-K filings describe financial results for specific quarters, appointments of new directors and executive officers, and equity-based compensation arrangements, including inducement grants under Nasdaq Listing Rule 5635(c)(4).
Through this page, users can also locate references to annual and quarterly reports (Forms 10-K and 10-Q) and related exhibits, where Edgewise discusses risk factors, liquidity, research and development expenses, and dependence on key product candidates such as sevasemten and EDG-7500. Disclosures frequently highlight that the company is clinical-stage, has not generated product revenue, and faces the typical uncertainties of drug development and regulatory approval.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand clinical, financial, and governance information. Users can also track insider and equity-related disclosures reported in 8-K exhibits and other filings to see how leadership and directors are compensated and how the company structures its incentive plans.
Edgewise Therapeutics (EWTX) filed a Form 4 showing insider activity. On 11/12/2025, a Director and Chief Scientific Officer exercised stock options and sold shares the same day. The insider exercised 100,000 options at an exercise price of $0.18 (code M) and sold 100,000 shares of common stock at an average price of $21.1245 (code S), with trades executed between $21.00 and $21.35.
Following these transactions, the insider directly beneficially owned 23,400 common shares. In addition, 1,147,365 derivative securities (stock options) remained beneficially owned. The exercised option referenced had become exercisable on 06/27/2021 and carries an expiration date of 06/27/2032.
Edgewise Therapeutics, Inc. director reports open-market share purchase. A reporting person who serves as a director of Edgewise Therapeutics, Inc. (EWTX) bought 10,700 shares of common stock on 11/11/2025 in an open-market transaction coded as a purchase. The shares were acquired at an average price of $18.6358 per share, with multiple trades executed in a price range from $18.55 to $18.65. Following this transaction, the director beneficially owns 23,702 shares of Edgewise Therapeutics common stock, held directly. The reporting person has indicated a willingness to provide detailed trade-by-trade pricing information upon request.
Edgewise Therapeutics, Inc. (EWTX) reported new equity awards to its Chief Financial Officer, Michael Nofi. On 11/10/2025, he received 43,750 restricted stock units (RSUs) that convert into the same number of common shares, vesting in four equal annual installments beginning on November 10, 2026. He was also granted stock options to purchase 262,500 shares of common stock at an exercise price of $18.28 per share. One quarter of these options vest on November 10, 2026, and the remaining options vest in equal monthly installments over the following three years, contingent on his continued service.
Edgewise Therapeutics, Inc. (EWTX) filed an initial ownership report on Form 3 for its Chief Financial Officer, who is an officer of the company but not a director or 10% owner. The event date for this ownership report is 11/10/2025. The filing states in the remarks that no securities are beneficially owned, indicating that the reporting person did not hold Edgewise Therapeutics equity at the time of this Form 3. The form is filed by one reporting person, with the signature provided by an attorney-in-fact under a power of attorney.
Edgewise Therapeutics (EWTX) appointed Michael Nofi as Chief Financial Officer, effective November 10, 2025, following the immediate retirement of CFO Michael Carruthers. The company stated Mr. Carruthers’ decision was not due to any disagreement. To support continuity, he is expected to remain an at-will employee until January 31, 2026 and then serve as a consultant until October 31, 2026.
Mr. Nofi brings 30+ years of finance leadership across life sciences, including six years as Chief Accounting Officer at SpringWorks Therapeutics. His compensation includes a $465,000 annual base salary and a target cash bonus equal to 40% of base salary. He will receive a stock option for 262,500 shares vesting 25% after one year and monthly thereafter over three years, and 43,750 restricted stock units vesting in four equal annual installments, each subject to continued service.
Edgewise Therapeutics (EWTX) filed its Q3 2025 10-Q, reporting a net loss of $40.7 million on operating expenses of $46.9 million. Research and development was $37.5 million and general and administrative was $9.4 million. Interest income contributed $6.2 million.
Liquidity remained strong with cash, cash equivalents and marketable securities of $563.3 million as of September 30, 2025, supported by an April 2025 underwritten registered direct offering of 9,935,419 shares at $20.13 per share for $200.0 million gross ($187.1 million net). For the first nine months, net cash used in operations was $105.2 million, reflecting continued investment in pipeline programs.
The company advanced multiple clinical assets: sevasemten in Phase 2 trials for Becker and Duchenne muscular dystrophy (including a pivotal cohort in Becker), EDG‑7500 in a multipart Phase 2 for hypertrophic cardiomyopathy, and EDG‑15400 in a Phase 1 study. Shares outstanding were 105,761,949 as of September 30, 2025, and 105,868,434 as of October 31, 2025. Management believes current liquidity will fund operations for at least the next 12 months.
Edgewise Therapeutics (EWTX) filed an 8-K stating it furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company notes that the information provided under Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished and not deemed filed under the Exchange Act.
Edgewise Therapeutics insider transactions by Russell Alan J: The reporting person executed transactions on 08/26/2025. The Form 4 shows an acquisition of 100,000 shares of common stock at a reported price of $0.18 and a sale of 100,000 shares at an average price of $14.5976 (range $14.40 to $14.825). After the non-derivative transactions, the reported beneficial ownership in common stock is 123,400 shares following the acquisition line and 23,400 shares following the sale line. The filing also reports ownership of derivative securities: a stock option (strike $0.18) for 100,000 shares exercisable from 06/27/2021 and expiring 06/27/2032, and a reported number of derivative-linked common shares beneficially owned of 1,247,365. The signature block shows the Form was signed by an attorney-in-fact on 08/28/2025.
Edgewise Therapeutics (EWTX) filed a Form 144 reporting a proposed sale of 100,000 shares of common stock to be executed through Morgan Stanley Smith Barney LLC on 08/26/2025 with an aggregate market value of $1,459,760.00. The filing shows 105,345,708 shares outstanding, indicating the proposed sale represents roughly 0.095% of outstanding shares. The shares were acquired on 08/26/2025 by exercise of options under a registered plan and paid in cash the same day. The filing also discloses a prior sale in the past three months: 1,907 shares sold on 08/12/2025 by Alan J Russell for $25,534.73. The filer certifies no undisclosed material adverse information.
Edgewise Therapeutics insider grant: The company reported that Robert Blaustein, Chief Development Officer and director, was granted 17,500 restricted stock units (RSUs) and options to purchase 105,000 shares on 08/12/2025. The RSUs are payable one-for-one upon vesting in four equal annual installments beginning 08/12/2026. The options have an exercise price of $13.39, vest at 1/48th monthly beginning 09/12/2025, and expire 08/12/2035. Following these grants Blaustein beneficially owns 17,500 RSUs and 105,000 option shares directly. The filing was signed by John R. Moore under power of attorney on 08/14/2025.